MitoRx Therapeutics has strengthened its leadership team by appointing Alison Strutt as CFO, László Tankó as Consultant CMO, and Sam Fazeli as Non-Executive Director. These hires come as MitoRx prepares to advance its lead drug candidate, MTRX31, a novel small molecule targeting mitochondrial dysfunction in metabolically unhealthy obesity, into clinical development. MTRX31 has shown promising preclinical results, including significant weight loss and improved metabolic health, potentially offering a new approach to obesity treatment. The new leadership will support MitoRx’s growth and strategic efforts to bring this innovative therapy to patients at high risk of obesity-related diseases.
Revenium introduced AI Insights, a tool that analyzes enterprise AI usage to pinpoint and rank budget waste, linking each issue to specific transactions for easy fixes. This helps companies recover costs by identifying inefficiencies like outdated mo...
KBR's Mission Technology Solutions secured a $95 million contract to enhance digital engineering and decision support for the U.S. Space Force. The five-year cost-plus-fixed-fee contract aims to accelerate space system development and improve mission...
AmpliTech Group's stock surged nearly 12% in premarket trading following the company's announcement of a significant Open RAN interoperability achievement at the O-RAN ALLIANCE Global PlugFest Spring 2026. The event validated AmpliTech's 64T64R Massi...
The S&P 500 rose 0.30% to close at 7,405.73 on Monday, recovering from last week's tech selloff driven by a strong rebound in semiconductor stocks like Micron, Nvidia, and Broadcom. Investor sentiment improved amid easing concerns over the AI rally l...
Cerebras stock opened at $350, nearly double its IPO price, signaling strong initial investor interest. However, the stock pulled back 20% the following day, causing uncertainty about its short-term prospects. Investors are now debating whether the d...
